References:
Ahmed, A. U., Auffinger, B., & Lesniak, M. S. (2013). Understanding
glioma stem cells: rationale, clinical relevance and therapeutic
strategies. Expert Review of Neurotherapeutics , 13 (5),
545-555. https://doi.org/10.1586/ern.13.42
Allen, M., Bjerke, M., Edlund, H., Nelander, S., & Westermark, B.
(2016). Origin of the U87MG glioma cell line: Good news and bad news.Science Translational Medicine , 8 (354), 354re353-354re353.
https://doi.org/10.1126/scitranslmed.aaf6853
Auffinger, B., Spencer, D., Pytel, P., Ahmed, A. U., & Lesniak, M. S.
(2015). The role of glioma stem cells in chemotherapy resistance and
glioblastoma multiforme recurrence. Expert Rev Neurother ,15 (7), 741-752.
https://doi.org/10.1586/14737175.2015.1051968
Binabaj, M. M., Bahrami, A., ShahidSales, S., Joodi, M., Joudi Mashhad,
M., Hassanian, S. M., Anvari, K., & Avan, A. (2018). The prognostic
value of MGMT promoter methylation in glioblastoma: A meta-analysis of
clinical trials. J Cell Physiol , 233 (1), 378-386.
https://doi.org/10.1002/jcp.25896
Costa, E. C., Moreira, A. F., de Melo-Diogo, D., Gaspar, V. M.,
Carvalho, M. P., & Correia, I. J. (2016). 3D tumor spheroids: an
overview on the tools and techniques used for their analysis.Biotechnol Adv , 34 (8), 1427-1441.
https://doi.org/10.1016/j.biotechadv.2016.11.002
Devarasetty, M., Dominijanni, A., Herberg, S., Shelkey, E., Skardal, A.,
& Soker, S. (2020). Simulating the human colorectal cancer
microenvironment in 3D tumor-stroma co-cultures in vitro and in vivo.Sci Rep , 10 (1), 9832.
https://doi.org/10.1038/s41598-020-66785-1
Di Cristofano, A., Kotsi, P., Peng, Y. F., Cordon-Cardo, C., Elkon, K.
B., & Pandolfi, P. P. (1999). Impaired Fas response and autoimmunity in
Pten+/- mice. Science , 285 (5436), 2122-2125.
https://doi.org/10.1126/science.285.5436.2122
Dominijanni, A. J., Devarasetty, M., Forsythe, S. D., Votanopoulos, K.
I., & Soker, S. (2021). Cell Viability Assays in Three-Dimensional
Hydrogels: A Comparative Study of Accuracy. Tissue Engineering
Part C: Methods , 27 (7), 401-410.
https://doi.org/10.1089/ten.tec.2021.0060
Donson, A. M., Addo-Yobo, S. O., Handler, M. H., Gore, L., & Foreman,
N. K. (2007). MGMT promoter methylation correlates with survival benefit
and sensitivity to temozolomide in pediatric glioblastoma. Pediatr
Blood Cancer , 48 (4), 403-407.
https://doi.org/10.1002/pbc.20803
Fedele, M., Cerchia, L., Pegoraro, S., Sgarra, R., & Manfioletti, G.
(2019). Proneural-Mesenchymal Transition: Phenotypic Plasticity to
Acquire Multitherapy Resistance in Glioblastoma. Int J Mol Sci ,20 (11). https://doi.org/10.3390/ijms20112746
Forsythe, S., Mehta, N., Devarasetty, M., Sivakumar, H., Gmeiner, W.,
Soker, S., Votanopoulos, K., & Skardal, A. (2019). Development of a
Colorectal Cancer 3D Micro-tumor Construct Platform From Cell Lines and
Patient Tumor Biospecimens for Standard-of-Care and Experimental Drug
Screening. Ann Biomed Eng .
https://doi.org/10.1007/s10439-019-02269-2
Frantz, C., Stewart, K. M., & Weaver, V. M. (2010). The extracellular
matrix at a glance. Journal of Cell Science , 123 (24),
4195-4200. https://doi.org/10.1242/jcs.023820
Fusenig, N. E., Capes-Davis, A., Bianchini, F., Sundell, S., & Lichter,
P. (2017). The need for a worldwide consensus for cell line
authentication: Experience implementing a mandatory requirement at the
International Journal of Cancer. PLOS Biology , 15 (4),
e2001438. https://doi.org/10.1371/journal.pbio.2001438
Gielen, P. R., Aftab, Q., Ma, N., Chen, V. C., Hong, X., Lozinsky, S.,
Naus, C. C., & Sin, W. C. (2013). Connexin43 confers Temozolomide
resistance in human glioma cells by modulating the mitochondrial
apoptosis pathway. Neuropharmacology , 75 , 539-548.
https://doi.org/10.1016/j.neuropharm.2013.05.002
Grek, C. L., Sheng, Z., Naus, C. C., Sin, W. C., Gourdie, R. G., &
Ghatnekar, G. G. (2018). Novel approach to temozolomide resistance in
malignant glioma: connexin43-directed therapeutics. Curr Opin
Pharmacol , 41 , 79-88.
https://doi.org/10.1016/j.coph.2018.05.002
Heimberger, A. B., Crotty, L. E., Archer, G. E., Hess, K. R., Wikstrand,
C. J., Friedman, A. H., Friedman, H. S., Bigner, D. D., & Sampson, J.
H. (2003). Epidermal growth factor receptor VIII peptide vaccination is
efficacious against established intracerebral tumors. Clin Cancer
Res , 9 (11), 4247-4254.
https://www.ncbi.nlm.nih.gov/pubmed/14519652
Hoarau-Véchot, J., Rafii, A., Touboul, C., & Pasquier, J. (2018).
Halfway between 2D and Animal Models: Are 3D Cultures the Ideal Tool to
Study Cancer-Microenvironment Interactions? Int J Mol Sci ,19 (1). https://doi.org/10.3390/ijms19010181
Jiang, J., Hoagland, D., Palatinus, J. A., He, H., Iyyathurai, J.,
Jourdan, L. J., Bultynck, G., Wang, Z., Zhang, Z., Schey, K., Poelzing,
S., McGowan, F. X., & Gourdie, R. G. (2019). Interaction of α Carboxyl
Terminus 1 Peptide With the Connexin 43 Carboxyl Terminus Preserves Left
Ventricular Function After Ischemia‐Reperfusion Injury. Journal of
the American Heart Association , 8 (16), e012385.
https://doi.org/10.1161/JAHA.119.012385
Lee, S. Y. (2016). Temozolomide resistance in glioblastoma multiforme.Genes Dis , 3 (3), 198-210.
https://doi.org/10.1016/j.gendis.2016.04.007
Malkki, H. (2016). Trial Watch: Glioblastoma vaccine therapy
disappointment in Phase III trial. Nat Rev Neurol , 12 (4),
190. https://doi.org/10.1038/nrneurol.2016.38
Maloney, E., Clark, C., Sivakumar, H., Yoo, K., Aleman, J., Rajan, S. A.
P., Forsythe, S., Mazzocchi, A., Laxton, A. W., Tatter, S. B., Strowd,
R. E., Votanopoulos, K. I., & Skardal, A. (2020). Immersion Bioprinting
of Tumor Organoids in Multi-Well Plates for Increasing Chemotherapy
Screening Throughput. Micromachines (Basel) , 11 (2).
https://doi.org/10.3390/mi11020208
Mazzocchi, A., Devarasetty, M., Herberg, S., Petty, W. J., Marini, F.,
Miller, L., Kucera, G., Dukes, D. K., Ruiz, J., Skardal, A., & Soker,
S. (2019). Pleural Effusion Aspirate for use in 3D Lung Cancer Modeling
and Chemotherapy Screening. ACS Biomater Sci Eng , 5 (4),
1937-1943. https://doi.org/10.1021/acsbiomaterials.8b01356
Mazzocchi, A. R., Rajan, S. A. P., Votanopoulos, K. I., Hall, A. R., &
Skardal, A. (2018). In vitro patient-derived 3D mesothelioma tumor
organoids facilitate patient-centric therapeutic screening. Sci
Rep , 8 (1), 2886.
https://doi.org/10.1038/s41598-018-21200-8
Montgomery, J., Richardson, W. J., Marsh, S., Rhett, J. M., Bustos, F.,
Degen, K., Ghatnekar, G. S., Grek, C. L., Jourdan, L. J., Holmes, J. W.,
& Gourdie, R. G. (2021). The connexin 43 carboxyl terminal mimetic
peptide αCT1 prompts differentiation of a collagen scar matrix in humans
resembling unwounded skin. Faseb j , 35 (8), e21762.
https://doi.org/10.1096/fj.202001881R
Munoz, J. L., Rodriguez-Cruz, V., Greco, S. J., Ramkissoon, S. H.,
Ligon, K. L., & Rameshwar, P. (2014). Temozolomide resistance in
glioblastoma cells occurs partly through epidermal growth factor
receptor-mediated induction of connexin 43. Cell Death &
Disease , 5 (3), e1145-e1145.
https://doi.org/10.1038/cddis.2014.111
Murphy, S. F., Varghese, R. T., Lamouille, S., Guo, S., Pridham, K. J.,
Kanabur, P., Osimani, A. M., Sharma, S., Jourdan, J., Rodgers, C. M.,
Simonds, G. R., Gourdie, R. G., & Sheng, Z. (2016). Connexin 43
Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide.Cancer Res , 76 (1), 139-149.
https://doi.org/10.1158/0008-5472.CAN-15-1286
Pridham, K. J., Shah, F., Hutchings, K. R., Sheng, K. L., Guo, S., Liu,
M., Kanabur, P., Lamouille, S., Lewis, G., Morales, M., Jourdan, J.,
Grek, C. L., Ghatnekar, G. G., Varghese, R., Kelly, D. F., Gourdie, R.
G., & Sheng, Z. (2022). Connexin 43 confers chemoresistance through
activating PI3K. Oncogenesis , 11 (1), 2.
https://doi.org/10.1038/s41389-022-00378-7
Roberts, R., Smyth, J. W., Will, J., Roberts, P., Grek, C. L.,
Ghatnekar, G. S., Sheng, Z., Gourdie, R. G., Lamouille, S., & Foster,
E. J. (2020). Development of PLGA nanoparticles for sustained release of
a connexin43 mimetic peptide to target glioblastoma cells. Mater
Sci Eng C Mater Biol Appl , 108 , 110191.
https://doi.org/10.1016/j.msec.2019.110191
Rubenstein, J. L., Li, J., Chen, L., Advani, R., Drappatz, J., Gerstner,
E., Batchelor, T., Krouwer, H., Hwang, J., Auerback, G., Kadoch, C.,
Lowell, C., Munster, P., Cha, S., Shuman, M. A., & Damon, L. E. (2013).
Multicenter phase 1 trial of intraventricular immunochemotherapy in
recurrent CNS lymphoma. Blood , 121 (5), 745-751.
https://doi.org/10.1182/blood-2012-07-440974
Rybinski, B., & Yun, K. (2016). Addressing intra-tumoral heterogeneity
and therapy resistance. Oncotarget , 7 (44), 72322-72342.
https://doi.org/10.18632/oncotarget.11875
Segerman, A., Niklasson, M., Haglund, C., Bergstrom, T., Jarvius, M.,
Xie, Y., Westermark, A., Sonmez, D., Hermansson, A., Kastemar, M.,
Naimaie-Ali, Z., Nyberg, F., Berglund, M., Sundstrom, M., Hesselager,
G., Uhrbom, L., Gustafsson, M., Larsson, R., Fryknas, M., . . .
Westermark, B. (2016). Clonal Variation in Drug and Radiation Response
among Glioma-Initiating Cells Is Linked to Proneural-Mesenchymal
Transition. Cell Rep , 17 (11), 2994-3009.
https://doi.org/10.1016/j.celrep.2016.11.056
Shen, X., Wu, S., Zhang, J., Li, M., Xu, F., Wang, A., Lei, Y., & Zhu,
G. (2020). Wild‑type IDH1 affects cell migration by modulating the
PI3K/AKT/mTOR pathway in primary glioblastoma cells. Mol Med Rep ,22 (3), 1949-1957. https://doi.org/10.3892/mmr.2020.11250
Simsa, R., Rothenbücher, T., Gürbüz, H., Ghosheh, N., Emneus, J.,
Jenndahl, L., Kaplan, D. L., Bergh, N., Serrano, A. M., & Fogelstrand,
P. (2021). Brain organoid formation on decellularized porcine brain ECM
hydrogels. PLoS ONE , 16 (1), e0245685.
https://doi.org/10.1371/journal.pone.0245685
Sivakumar, H., Devarasetty, M., Kram, D. E., Strowd, R. E., & Skardal,
A. (2020). Multi-Cell Type Glioblastoma Tumor Spheroids for Evaluating
Sub-Population-Specific Drug Response. Frontiers in bioengineering
and biotechnology , 8 , 538663-538663.
https://doi.org/10.3389/fbioe.2020.538663
Sivakumar, H., Strowd, R., & Skardal, A. (2017). Exploration of Dynamic
Elastic Modulus Changes on Glioblastoma Cell Populations with Aberrant
EGFR Expression as a Potential Therapeutic Intervention Using a Tunable
Hyaluronic Acid Hydrogel Platform. Gels , 3 (3).
https://doi.org/10.3390/gels3030028
Sottoriva, A., Spiteri, I., Piccirillo, S. G., Touloumis, A., Collins,
V. P., Marioni, J. C., Curtis, C., Watts, C., & Tavare, S. (2013).
Intratumor heterogeneity in human glioblastoma reflects cancer
evolutionary dynamics. Proc Natl Acad Sci U S A , 110 (10),
4009-4014. https://doi.org/10.1073/pnas.1219747110
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B.,
Taphoorn, M. J., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U.,
Curschmann, J., Janzer, R. C., Ludwin, S. K., Gorlia, T., Allgeier, A.,
Lacombe, D., Cairncross, J. G., Eisenhauer, E., Mirimanoff, R. O., . . .
National Cancer Institute of Canada Clinical Trials, G. (2005).
Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med , 352 (10), 987-996.
https://doi.org/10.1056/NEJMoa043330
Swartz, A. M., Li, Q. J., & Sampson, J. H. (2014). Rindopepimut: a
promising immunotherapeutic for the treatment of glioblastoma
multiforme. Immunotherapy , 6 (6), 679-690.
https://doi.org/10.2217/imt.14.21
Taal, W., Oosterkamp, H. M., Walenkamp, A. M., Dubbink, H. J.,
Beerepoot, L. V., Hanse, M. C., Buter, J., Honkoop, A. H., Boerman, D.,
de Vos, F. Y., Dinjens, W. N., Enting, R. H., Taphoorn, M. J., van den
Berkmortel, F. W., Jansen, R. L., Brandsma, D., Bromberg, J. E., van
Heuvel, I., Vernhout, R. M., . . . van den Bent, M. J. (2014).
Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma
(BELOB trial): a randomised controlled phase 2 trial. Lancet
Oncol , 15 (9), 943-953.
https://doi.org/10.1016/S1470-2045(14)70314-6
Tang, C., Guo, J., Chen, H., Yao, C. J., Zhuang, D. X., Wang, Y., Tang,
W. J., Ren, G., Yao, Y., Wu, J. S., Mao, Y., & Zhou, L. F. (2015). Gene
mutation profiling of primary glioblastoma through multiple tumor biopsy
guided by 1H-magnetic resonance spectroscopy. Int J Clin Exp
Pathol , 8 (5), 5327-5335.
https://www.ncbi.nlm.nih.gov/pubmed/26191234
Verhaak, R. G., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson,
M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., Alexe, G.,
Lawrence, M., O’Kelly, M., Tamayo, P., Weir, B. A., Gabriel, S.,
Winckler, W., Gupta, S., Jakkula, L., . . . Cancer Genome Atlas
Research, N. (2010). Integrated genomic analysis identifies clinically
relevant subtypes of glioblastoma characterized by abnormalities in
PDGFRA, IDH1, EGFR, and NF1. Cancer Cell , 17 (1), 98-110.
https://doi.org/10.1016/j.ccr.2009.12.020
Votanopoulos, K. I., Forsythe, S., Sivakumar, H., Mazzocchi, A., Aleman,
J., Miller, L., Levine, E., Triozzi, P., & Skardal, A. (2019). Model of
Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening:
Feasibility Study. Ann Surg Oncol .
https://doi.org/10.1245/s10434-019-08143-8
Votanopoulos, K. I., Mazzocchi, A., Sivakumar, H., Forsythe, S., Aleman,
J., Levine, E. A., & Skardal, A. (2019). Appendiceal Cancer
Patient-Specific Tumor Organoid Model for Predicting Chemotherapy
Efficacy Prior to Initiation of Treatment: A Feasibility Study.Ann Surg Oncol , 26 (1), 139-147.
https://doi.org/10.1245/s10434-018-7008-2
Votanopoulos, K. I., & Skardal, A. (2020). ASO Author Reflections:
Co-cultured Lymph Node and Tumor Organoids as a Platform for the
Creation of Adaptive Immunity and Predict Response to Immunotherapy.Ann Surg Oncol . https://doi.org/10.1245/s10434-020-08351-7
Zhang, J., Stevens, M. F., & Bradshaw, T. D. (2012). Temozolomide:
mechanisms of action, repair and resistance. Curr Mol Pharmacol ,5 (1), 102-114. https://doi.org/10.2174/1874467211205010102